Auven Therapeutics Announces the Appointment of Beth P. Hecht as a New Partner
October 29, 2012
Auven Therapeutics Announces the Appointment of a New Partner
Read the full press release
ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D
July 17, 2012
ADC Therapeutics (ADCT), the drug development company targeting cancers with antibody-drug conjugate (ADC) “warhead” therapies, today announced the appointment of former Genmab Vice President Dr Patrick van Berkel as Senior Vice President, Research & Development.
Read the full press release
Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates
July 06, 2012
Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates
Read the full press release
Seattle Genetics announces preclinical results in ADCs from collaboration with Spirogen
April 03, 2012
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR) being held in Chicago, IL.
Read the full press release
Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs
April 03, 2012
Celtic TherapeuticsManagement L.L.L.P. the global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody‐Drug‐Conjugate (“ADC”) products, with the launchof a new Switzerland‐based company.
Read the full press release